

04/07/2005

10/612,497

### FOREIGN PATENT DOCUMENTS

I.O.

European Patent 0 239 400, (Winter) published August 3, 1994.

### OTHER DOCUMENTS

Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," *Nature*, 321:522-525 (1986).

Morrison, "Transfectomas provide novel chimeric antibodies," *Science*, 229:1202-1207 (1985).

Oi et al., "Chimeric antibodies," *Biotechniques*, 4(3):214-221 (1986).

Neuberger et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function," *Nature*, 314:268-270 (1985).

O'Kennedy et al., "Antibody engineering: an overview," *Essays in Biochemistry*, 46:59-75 (1991).

Parren, "Preparation of genetically engineered monoclonal antibodies for human immunotherapy," *Human Antibodies and Hybridomas*, 3:137-145 (1992).

Riechmann et al., "Reshaping human antibodies for therapy," *Nature*, 332:323-327 (1988).

Vaswani et al., "Humanized antibodies as potential therapeutic drugs," *Annals of Allergy, Asthma & Immunology*, 81:105-119 (1998).

Verhoeyen et al., "Reshaping human antibodies: grafting an antilysozyme activity," *Science*, 239:1534-1536 (1988).

I.O.

Wu, "From esoteric theory to therapeutic antibodies," *Applied Biochemistry and Biotechnology*, 47(2/3):107-118 (1994).

Ilia Ouspenski 06/27/2005

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANTS	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
	APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
	FILING DATE July 1, 2003	GROUP 1446 1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
I.O.	6,255,458	07/03/01	Lonberg et al.	530	388.15	
	6,207,156	03/27/01	Kuchroo et al.	424	154.1	
	6,162,963	12/19/00	Kucherlapati et al.	800	18	
	6,150,584	11/21/00	Kucherlapati et al.	800	18	
	6,114,598	09/05/00	Kucherlapati et al.	800	18	
	6,075,181	06/13/00	Kucherlapati et al.	800	25	
	6,051,227	04/18/00	Allison et al.	424	144.1	
	5,977,318	11/02/99	Linsley et al.	530	388.1	
	5,968,510	10/19/99	Linsley et al.	424	141.1	
	5,939,598	08/17/99	Kucherlapati et al.	800	25	
	5,916,771	06/29/99	Hori et al.	435	69.6	
	5,865,887	01/05/99	Allison et al.	424	144.1	
	5,827,690	10/27/98	Meade et al.	435	69.6	
	5,814,318	09/29/98	Lonberg et al.	424	184.1	
	5,811,097	09/22/98	Allison et al.	424	144.1	
	5,789,650	08/04/98	Lonberg et al.	800	2	
	5,789,215	08/04/98	Berns et al.	435	172.3	
	5,777,085	07/07/98	Co et al.	530	388.23	
	5,773,253	06/30/98	Linsley et al.	435	69.7	
	5,770,429	06/23/98	Lonberg et al.	435	240.2	
	5,770,197	06/23/98	Linsley et al.	424	134.1	
	5,756,687	05/26/98	Denman et al.	530	412	
	5,750,172	05/12/98	Meade et al.	426	580	
	5,741,957	04/21/98	Deboer et al.	800	2	
	5,733,743	03/31/98	Johnson et al.	435	69.1	
	5,721,367	02/24/98	Kay et al.	800	2	
	5,714,350	02/03/98	Co et al.	435	69.6	
I.O.	5,703,057	12/30/97	Johnston et al.	514	44	

EXAMINER

Ilian Ouspenski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/812,497
		APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
		FILING DATE July 1, 2003	GROUP <del>4116</del> 1644

I.O.	5,697,902	12/16/97	Goldenberg	604	49
	5,693,792	12/02/97	Torii et al.	540	358
	5,693,761	12/02/97	Queen et al.	536	23.53
	5,661,016	08/26/97	Lonberg et al.	435	172.3
	5,648,471	07/15/97	Buttram et al.	424	1.49
	5,643,763	07/01/97	Dunn et al.	435	91.1
	5,633,425	05/27/97	Lonberg et al.	800	2
	6,625,128	04/29/97	Lonberg et al.	800	2
	5,612,205	03/18/97	Kay et al.	435	172.3
	5,591,669	01/07/97	Krimpenfort et al.	800	2
	5,585,089	12/17/96	Queen et al.	424	133.1
	5,569,825	10/29/96	Lonberg et al.	800	2
	5,545,807	08/13/96	Surani et al.	800	2
	5,545,806	08/13/96	Lonberg et al.	800	2
	5,530,101	06/25/96	Queen et al.	530	387.2
	5,434,131	07/18/95	Linsley et al.	514	2
	5,194,594	03/16/93	Khawli et al.	530	391.5
	5,151,510	09/29/92	Stec et al.	536	27
	RE 35,500	05/06/97	Rhodes	424	1.49
	6,102,990	04/07/93	Rhodes	530	391.5
	5,101,827	04/07/92	Goldenberg	128	653.4
	4,959,455	09/25/90	Clark et al.	530	351
	4,921,040	03/27/90	Kaufman et al.	435	69.6
	4,816,397	03/28/89	Boss et al.	435	68
	4,740,461	04/26/88	Kaufman	435	68
	4,735,210	04/05/88	Goldenberg	128	654
	4,683,202	07/28/87	Mullis	435	91
	4,683,195	07/28/87	Mullis et al.	435	6
	4,681,581	07/21/87	Coates	604	391
	4,399,216	08/16/83	Axel et al.	435	6
I.O.	2002/0086014	07/04/02	Korman et al.	424	144.1

EXAMINER

Ilion Ouspenski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
		APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
		FILING DATE July 1, 2003	GROUP <del>4118</del> 1644

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
I.O.	CA 2,205,680	11/16/98	Canada	A61K	38/17		
	EP 0 546 073	06/16/93	Europe	C12N	15/13		
	EP 0 463 151	01/02/92	Europe	C12N	15/00		
	EP 0 338 841	10/25/89	Europe	C12N	15/00		
	EP 0 323 997	07/19/89	Europe	C12N	15/12		
	EP 0 256 055	02/24/88	Europe	C12N	15/52		
	EP 0 216 846	04/08/87	Europe	C12N	15/00		
	WO 01/14424	03/01/01	PCT	C07K	16/00		
	WO 00/32231	06/08/00	PCT	A61K	39/395		
	WO 98/50433	11/12/98	PCT	C07K	16/28		
	WO 98/46996	10/22/98	PCT	G01N	33/53		
	WO 98/42752	10/01/98	PCT	C07K	16/28		
	WO 98/24893	06/11/98	PCT	C12N	15/00		
	WO 98/24884	06/11/98	PCT	C12N	5/00		
	WO 97/38137	10/16/97	PCT	C12Q	1/68		
	WO 97/20574	06/12/97	PCT	A61K	38/16		
	WO 97/13852	04/17/97	PCT	C12N	15/00		
	WO 96/34098	10/31/96	PCT	C12N	15/00		
	WO 96/33735	10/31/96	PCT	A61K	39/00		
	WO 96/22380	07/25/96	PCT	C12N	15/87		
	WO 96/14436	05/17/96	PCT	C12Q	1/68		
	WO 95/33770	12/14/95	PCT	C07K	14/705		
	WO 95/24217	09/14/95	PCT	A61K	39/395		
	WO 95/03408	02/02/95	PCT	C12N	15/12		
	WO 95/01994	01/19/95	PCT	C07K	14/705		
	WO 94/29444	12/22/94	PCT	C12N	15/11		
	WO 94/25585	11/10/94	PCT	C12N	15/00		
I.O.	WO 94/02802	02/03/94	PCT	C12N	15/00		

EXAMINER

Ilian Ouspenski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
		APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
		FILING DATE July 1, 2003	GROUP <del>1116</del> 1644

I.O.	WO 94/00569	01/06/94	PCT	C12N	15/00		
	WO 93/12227	06/24/93	PCT	C12N	15/00		
	WO 93/00431	01/07/93	PCT	C12N	15/12		
	WO 92/22670	12/23/92	PCT	C12Q	1/68		
	WO 92/22647	12/23/92	PCT	C12N	15/00		
	WO 92/22645	12/23/92	PCT	C12N	15/00		
	WO 92/03918	03/19/92	PCT	A01H	1/00		
	WO 91/10741	07/25/91	PCT	C12P	21/06		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Alegre et al., "Regulation of surface and intracellular expression of CTLA4 on mouse T cells," <i>J. Immunol.</i> , 157:4762-4770 (1996)
	Allison & Krummel, "The Yin and Yang of T cell costimulation," <i>Science</i> , 270:932-933 (1995)
	Balzano et al., "CTLA-4 and CD28: Similar proteins, neighbouring genes," <i>Int'l J Cancer Suppl.</i> , 7:28-32 (1992)
	Barker and Dayhoff, "Detecting distant relationships: computer methods and results," <i>Atlas of Protein Sequence and Structure</i> , pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972))
	Blair et al., "Cutting edge: CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-XL induction," <i>J Immunol</i> , 160:12-15 (1998)
	Blake and Litzi-Davis, "Evaluation of peptide libraries: An iterative strategy to analyze the reactivity of peptide mixtures with antibodies," <i>BioConjugate Chem.</i> , 3:510-513 (1992)
	Boussiotis et al., "Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation," <i>Proc Natl Acad Sci USA</i> , 90:11059-11063 (1993)
	Bowie et al., "A method to identify protein sequences that fold into a known three-dimensional structure," <i>Science</i> , 253:164-170 (1991)
	Bruggemann et al., "A repertoire of monoclonal antibodies with human heavy chains from transgenic mice," <i>PNAS USA</i> , 86:6709-6713 (1989)
	Bruggemann and Neuberger, "Generation of antibody repertoires in transgenic mice," <i>Methods: A companion to Methods in Enzymology</i> , 2:159-165 (1991)
I.O.	Bruggemann et al., "Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus," <i>Eur. J. Immunol.</i> 21:1323-1326 (1991)

EXAMINER

Ilia Ouspenski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/812,497
INFORMATION DISCLOSURE STATEMENT BY APPLICANTS		APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
		FILING DATE July 1, 2003	GROUP 4116 1644

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
I.O.	Bruggemann, M. and Neuberger, M.S. "Strategies for expressing human antibody repertoires in transgenic mice," <i>Immunology Today</i> , 17:391-397 (1996)
	Brunet et al., "A new member of the immunoglobulin superfamily - CTLA-4," <i>Nature</i> , 328:267-270 (1987)
	Bumpers et al., "Consistent hepatic metastasis of human colorectal cancer in severe combined immunodeficient mice," <i>J. Surgical Res.</i> , 61:282-288 (1996)
	Castan et al., "Accumulation of CTLA-4 expressing T lymphocytes in the germinal centres of human lymphoid tissues," <i>Immunology</i> , 90:265-271 (1997)
	Chen et al., "Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules Cd28 and CTLA-4," <i>Cell</i> 71:1093-1102 (1992)
	Chen et al., "Immunoglobulin gene rearrangement in B-cell deficient mice generated by targeted deletion of the JH locus," <i>International Immunology</i> , 5:647-656 (1993)
	Chen et al., "Intracellular antibodies as a new class of therapeutic molecules for gene therapy," <i>Human Gene Therapy</i> , 5:595-601 (1994)
	Chiswell and McCafferty, "Phage antibodies: will new 'colidonal' antibodies replace monoclonal antibodies?" <i>TIBTECH</i> , 10:80-84 (1992)
	Choi et al., "Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome," <i>Nature Genetics</i> , 4:117-123 (1993)
	Chothia & Lesk, "Canonical structures for the hypervariable regions of immunoglobulins," <i>J. Mol. Biol.</i> , 196:901-917 (1987)
	Chothia et al., "Conformations of immunoglobulin hypervariable regions," <i>Nature</i> , 342:877-883 (1989)
	Chuang et al., "Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression," <i>J. Immunol.</i> , 159:144-151 (1997)
	Colligan et al., "Unit 2.1, "Enzyme-linked immunosorbent assays," <i>Current protocols in immunology</i> , 2.1.1-2.1.22 (1994)
	Cwirla et al., "Peptides on phage: a vast library of peptides for identifying ligands," <i>PNAS USA</i> , 87:6378-6382 (1990)
	Dariavach et al., "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains," <i>Eur. J. Immunol.</i> , 18:1901-1905 (1988)
I.O.	Dayhoff, "Survey of new data and computer methods of analysis," <i>Atlas of Protein Sequence and Structure</i> , pp. 1-10 (Volume 5, Supplement 2, National Biomedical Research Foundation (1976))

EXAMINER

Dier Ouspenski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
INFORMATION DISCLOSURE STATEMENT BY APPLICANTS		APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
		FILING DATE July 1, 2003	GROUP <del>4416</del> 1646

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
I.O.	de Boer et al., "Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells," <i>Eur J Immunol</i> , 23:3120-3125 (1993)
	Evans et al., "Design of nonpeptidic ligands for a peptide receptor: cholecystokinin antagonists," <i>J. Med. Chem.</i> , 30:1229 (1987)
	Fallarino et al., "B7-1 Engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28," <i>J Exp Med</i> , 188:205-210 (1998)
	Fanger et al., "Production and use of anti-FcR bispecific antibodies," <i>Immunol Methods</i> , 4:72-81 (1994)
	Fauchere, J., "Elements for the rational design of peptide drugs," <i>Adv. Drug Res.</i> , 15:29-69 (1986)
	Fishwild et al., "High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice," <i>Nature Biotech.</i> , 4:845-851 (1996)
	Foster et al., "Molecular Mechanisms and Selective Influences That Shape the Kappa Gene Repertoire of IgM <sup>+</sup> B Cells," <i>J. Clin. Invest.</i> , 99:1614-27 (1997).
	Freeman et al., "Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production," <i>J Exp Med.</i> , 178:2185-192 (1993)
	Freeman et al., "Uncovering of functional alternative CTLA-4 counter-receptor in B7- deficient mice," <i>Science</i> , 262:907-909 (1993)
	Freeman et al., "The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor," <i>J Immunol</i> , 161:2708-2715 (1998)
	Fry et al., "Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor," <i>Proc Natl Acad Sci USA</i> , 95:12022-12027 (1998)
	Furet et al., "Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411," <i>J of Computer-Aided Molecular Design</i> , 9:465-472 (1995)
	Galfre and Milstein, "Preparation of monoclonal antibodies: strategies and procedures," <i>Methods Enzymol.</i> , 73:3-46 (1981)
	Ginalski et al., "Modelling of active forms of protein kinases: p38 - a case study," <i>Acta Biochimica Polonica</i> , 44:557-564 (1997)
I.O.	Gorman et al., "The rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection," <i>Proc Natl Acad Sci USA</i> , 79:6777 (1982)

EXAMINER

Ilia Ouspenski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANTS	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
	APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
	FILING DATE July 1, 2003	GROUP <del>4418</del> 1646

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
I.O.	Green et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs," <i>Nature Genetics</i> , 7:13-21 (1994)
	Green and Jakobovits, "Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes," <i>J. Exp. Med.</i> , 188:483-495 (1998)
	Gribben et al., "CTLA4 mediates antigen specific apoptosis of human T cells," <i>Proc. Natl. Acad. Sci.</i> , 92:811-815 (1995)
	Grosschedl and Baltimore, "Cell-type specificity of immunoglobulin gene expression is regulated by at least three DNA sequence elements," <i>Cell</i> , 41:885-897 (1985)
	Hanes and Plückthun, "In vitro selection and evolution of functional proteins by using ribosome display," <i>Proc Natl Acad Sci USA</i> , 94:4937-4942 (1997)
	Harding et al., "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones," <i>Nature</i> , 356:607-609 (1992)
	Harper et al., "CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location," <i>J Immunol</i> , 147:1037-1044 (1991)
	Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," <i>Science</i> , 262:905-907 (1993)
	Hofmann et al., "A model of Cdc25 phosphatase catalytic Domain and Cdk-interaction surface based on the presence of a rhodanese homology domain," <i>J Mol Biol</i> , 282:195-208 (1998)
	Holliger et al., "Diabodies": Small bivalent and bispecific antibody fragments," <i>PNAS USA</i> 90:6444-6448 (1993)
	Hoogenboom et al., "Building antibodies from their genes," <i>Immunol. Reviews</i> , 130:43-68 (1992)
	Horspool et al., "Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4," <i>J Immunol</i> , 160:2706-2714 (1998)
	Houghten, "General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids," <i>Proc Natl Acad Sci USA</i> , 82:5131-5135 (1985)
I.O.	Houghten et al., "The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides," <i>Biotechniques</i> , 13:412-421 (1992)

EXAMINER

Ilia Ouspewski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANTS	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
	APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
	FILING DATE July 1, 2003	GROUP <del>4446</del> 1644

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
J.O.	Hurwitz et al., "Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis," <i>J Neuroimmunol</i> , 73:57-62 (1997)
	Hurwitz et al., "CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma," <i>Proc Natl Acad Sci USA</i> , 95:10067-10071 (1998)
	Ill et al., "Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions," <i>Protein Engineering</i> , 10:949-957 (1997)
	Jakobovits et al., "Germ-line transmission and expression of a human-derived yeast artificial-chromosome," <i>Nature</i> , 362:255-258 (1993)
	Jakobovits, et al., "Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production," <i>Proc. Natl. Acad. Sci. USA</i> , 90:2551-2555 (1993)
	Jakobovits, "Humanizing the mouse genome," <i>Current Biology</i> , 4:761-763 (1994)
	Jakobovits, "Production of fully human antibodies by transgenic mice," <i>Current Opinion in Biotechnology</i> , 6:561-566 (1995)
	Jakobovits, "The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice," <i>Expert Opinion on Investigational Drugs</i> , 7:607-614 (1998)
	Joukov et al., "Identification of Csk tyrosine phosphorylation sites and a tyrosine residue important for kinase domain structure," <i>Biochem J</i> , 322:927-935 (1997)
	Junghans et al., "Antibody-based immunotherapies for cancer," <i>Cancer Chemotherapy and Biotherapy</i> , 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996))
	Kostelny et al., "Formation of a bispecific antibody by the use of leucine zippers," <i>J. Immunol.</i> , 148:1547-1553 (1992)
	Krummel and Allison, "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation," <i>J Exp Med</i> , 182:459-465 (1995)
	Krummel et al., "Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo," <i>Int Immunol</i> , 8:519-523 (1996)
J.O.	Kuchroo et al., "B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy," <i>Cell</i> , 80:707-718 (1995)

EXAMINER

Ilia Ouspenski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANTS	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
	APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
	FILING DATE July 1, 2003	GROUP <del>4416</del> 1644

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
J.O.	Kwon et al., "Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer," <i>Proc Natl Acad Sci USA</i> , 94:8099-8103 (1997)
	LaPlanche et al., "Phosphorothioate-modified oligodeoxynucleotides. III NMR and UV spectroscopic studies of the R <sub>p</sub> -R <sub>p</sub> , S <sub>p</sub> -S <sub>p</sub> duplexes. [d(GG <sub>2</sub> AATTCC) <sub>2</sub> derived from diastereomeric O-ethyl phosphorothioates," <i>Nucl. Acids Res.</i> , 14:9081 (1986)
	Lenschow et al., "Expression and functional significance of an additional ligand for CTLA-4," <i>Proc Natl Acad Sci USA</i> , 90:11054-11058 (1993)
	Lenschow et al., "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg," <i>Science</i> , 257:789-792 (1992)
	"Leucocyte Typing VI: White Cell Differentiation Antigens," <i>Garland Publishing</i> , New York, NY, pp 30-31, 95-98 and 1213-1214.
	Lin et al., "Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28," <i>J Exp Med</i> , 188:199-204 (1998)
	Linsley et al., "CTLA-4 is a second receptor for the B cell activation antigen B7," <i>J. Exp. Med.</i> , 174:561-569 (1991)
	Linsley et al., "Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes," <i>J Exp Med</i> , 176:1595-1604 (1992)
	Linsley et al., "Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule," <i>Science</i> , 257:792-795 (1992)
	Liu et al., "Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity," <i>J. Immunol.</i> , 139:3521-3528 (1987)
	Liu et al., "Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells," <i>Proc Natl Acad Sci USA</i> , 84:3439-3443 (1987)
	Lonberg et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," <i>Nature</i> , 368:856-859 (1994)
	Löhder et al., "Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes," <i>J Exp Med</i> , 187:427-432 (1998)
J.O.	Mandel et al., "ABGEN: A knowledge-based automated approach for antibody structure modeling," <i>Nature Biotechnology</i> , 14:323-328 (1996)

EXAMINER

Dina Onspenshi

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
INFORMATION DISCLOSURE STATEMENT BY APPLICANTS		APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
		FILING DATE July 1, 2003	GROUP <del>4418</del> 1644

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
J.O.	Marasco, "Intrabodies: turning the humoral immune system outside in for intracellular immunization," <i>Gene Therapy</i> , 4:11-15 (1997)
	Markees et al., "Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon- $\gamma$ , and CTLA4," <i>J Clin Invest</i> , 101:2446-2455 (1998)
	Marks et al., "Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes," <i>Eur. J. Immunol.</i> , 21:885-891 (1991)
	Marrack, et al., "The Staphylococcal Enterotoxins and Their Relatives," <i>Science</i> , 705-711 (1980)
	Martin et al., "The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6," <i>The EMBO Journal</i> , 13:5303-5309 (1994)
	McCoy et al., "Protective immunity to nematode infection is induced by CTLA-4 blockade," <i>J Exp Med</i> , 186:183-187 (1997)
	Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice," <i>Nature Genetics</i> , 15:146-156 (1997)
	Monfardini et al., "Rational design, analysis, and potential utility of GM-CSF antagonists," <i>Proc Assoc Am Physicians</i> , 108:420-431 (1996)
	Murphy et al., "Blockade of CTLA-4 enhances host resistance to the intercellular pathogen, <i>Leishmania donovani</i> ," <i>J. Immunol.</i> , 161:4153-4160 (1998)
	Needleman and Wunsch, "A general method applicable to the search for similarities in the amino acid sequence to two proteins," <i>Mol. Biol.</i> , 48:443-453 (1970)
	Okayama et al., "A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells," <i>Mol. Cell. Bio.</i> , 3:280-289 (1983)
	Parnley and Smith, "Antibody-selectable filamentous fd phage vectors: affinity purification of target genes," <i>Gene</i> , 73:305-318 (1988)
	Pearson and Lipman, "Improved tools for biological sequence comparison," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 85:2444-2448 (1988)
	Perez et al., "Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement," <i>Immunity</i> , 6:411-417 (1997)
J.O.	Perrin et al., "B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis," <i>Immunol Res</i> , 14:189-199 (1995)

EXAMINER

Jillia Casperesi

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANTS	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
	APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
	FILING DATE July 1, 2003	GROUP <del>4116</del> 1644

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
J.O.	Perrin et al., "CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis" <i>J Immunol</i> , 157:1333-1336 (1996)
	Pinilla et al., "Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries," <i>Biotechniques</i> , 13:901-905 (1992)
	Powell et al., "Compendium of excipients for parenteral formulations," <i>PDA J Pharm Sci Technol</i> , 52:238-311 (1998)
	Razi-Wolf et al., "Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor," <i>Proc Natl Acad Sci USA</i> , 90:11182-11186 (1993)
	Rizo and Gierasch, "Constrained peptides: models of bioactive peptides and protein substructure," <i>Ann. Rev. Biochem.</i> , 61:387-418 (1992)
	Russel et al., "Retroviral vectors displaying functional antibody fragments," <i>Nucl. Acids Research</i> , 21:1081-1085 (1993)
	Schwartz, "Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy," <i>Cell</i> , 71:1065-1068 (1992)
	Scott, "Discovery peptide ligands using epitope libraries," <i>Trends In Biochemical Sciences</i> , 17:241-245 (1992)
	Singh et al., "Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases," <i>J Med Chem</i> , 40:1130-1136 (1997)
	Smith and Waterman, "Comparison of Blosequences," <i>Adv. Appl. Math.</i> , 2:482-489 (1981)
	Songsivilai and Lachmann, "Bispecific antibody: a tool for diagnosis and treatment of disease," <i>Clin. Exp. Immunol.</i> , 79: 315-321 (1990)
	Stec et al., "Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxynucleotides," <i>J. Am. Chem. Soc.</i> , 106:6077-6079 (1984)
	Stein et al., "Physicochemical properties of phosphorothioate oligodeoxynucleotides," <i>Nucl. Acids Res.</i> , 16:3209-3221 (1988)
	Taylor et al., "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins," <i>Nucleic Acids Research</i> , 20:6287-6295 (1992)
	Taylor et al., "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM," <i>International Immunology</i> , 6:579-591 (1994)
J.O.	Thornton et al., "Prediction of progress at last" <i>Nature</i> , 354:105-106 (1991)

EXAMINER

Eric Ouspenski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
INFORMATION DISCLOSURE STATEMENT BY APPLICANTS		APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
		FILING DATE July 1, 2003	GROUP <del>4416</del> 1644

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
I.O.	Tivol et al., "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4," <i>Immunity</i> , 3:541-547 (1995)
	Townsend and Allison, "Tumor rejection after direct costimulation of CD8 <sup>+</sup> T cells by B7-transfected melanoma cells," <i>Science</i> , 259:368-370 (1993)
	Trautenecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," <i>EMBO J</i> , 10:3655-3659 (1991)
	Trautenecker et al., "Janusin: new molecular design for bispecific reagents," <i>Int. J. Cancer (Suppl.)</i> , 7:51-52 (1992)
	Tuailon et al., "Analysis of direct and inverted DJH rearrangements in a human Ig heavy chain transgenic minilocus," <i>J. Immunol.</i> , 154:6453-6465 (1995)
	Tuailon et al., "Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: gene-segment use in $\mu$ and $\gamma$ transcripts," <i>Proc. Natl. Acad. Sci. USA</i> , 90:3720-3724 (1993)
	Uhlmann and Peyman, "Antisense RNA: A natural gene expression control system," <i>Chemical Reviews</i> , 90:543 (1990)
	Van Parijs et al., "Role of interleukin 12 and costimulators in T cell anergy in vivo," <i>The Journal of Experimental Medicine</i> , 188, 1119-1128 (1997)
	Veber and Freidinger, "The design of metabolically-stable peptide analogs," <i>Trends In Neuro Sciences</i> , p.392 (1985)
	Vitetta et al., "Immunotoxins: magic bullets or misguided missiles," <i>Immunol Today</i> , 14:252-259 (1993)
	Walunas et al., "CTLA-4 can function as a negative regulator of T cell activation," <i>Immunity</i> , 1:405-413 (1994)
	Walunas et al., "CTLA-4 ligation blocks CD28-dependent T cell activation," <i>J Exp Med</i> , 183:2541-2550 (1996)
	Waterhouse et al., "Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4," <i>Science</i> , 270:985-988 (1995)
	Winter and Harris, "Humanized Antibodies," <i>Immunology Today</i> , 14:243-246 (1993)
	Wright et al., "Genetically engineered antibodies: Progress and prospects," <i>Crit. Reviews in Immunol.</i> , 12:125-168 (1992)
I.O.	Yang et al., "Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages," <i>Cancer Res</i> , 57:4036-4041 (1997)

EXAMINER

Ilia Auspensi

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANTS	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
	APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
	FILING DATE July 1, 2003	GROUP <del>1116</del> 1644

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
J.O.	Yi-qun et al., "Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens," <i>Int Immunol</i> , 8:37-44 (1996)
J.O.	Zon et al., "Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions," <i>Anti-Cancer Drug Design</i> , 6:539-568 (1991)
J.O.	Zon et al., "Phosphorothioate oligonucleotides," <i>Oligonucleotides and Analogues: A Practical Approach</i> , pp. 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991))

EXAMINER

Ilion Aspenshi

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.